English
This article is from Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association , volume 18 . Abstract Hepatitis B virus (HBV) reactivation is a well-recognized complication that occurs in lymphoma patients who undergo chemotherapy. Only very few cases of HBV reactivation in patients with isolated antibody against hepatitis B surface antigen (anti-HBs) have been reported. We present a case of a 78-year-old woman diagnosed with diffuse large B cell non-Hodgkin's lymphoma who only displayed a positive anti-HBs, as the single possible marker of occult HBV infection, before starting therapy. She was treated with several chemotherapeutic regimens (including rituximab) for disease relapses during 3 years. Forty days after the last cycle of chemotherapy, she presented with jaundice, markedly elevated serum aminotransferase levels, and coagulopathy. HBV serology showed positivity for HBsAg, anti-HBc and anti-HBs. HBV DNA was positive. Antiviral treatment with entecavir was promptly initiated, but the patient died from liver failure. A review of the literature of HBV reactivation in patients with detectable anti-HBs levels is discussed.
Sign in with your free account to read, download EPUBs or listen.
Ebook · Fatal Hepatitis B Reactivation Treated With Entecavir in an Isolated Anti-HBs Positive Lymphoma Patient: A Case Report and Literature Review. · Ferreira, Rosa, Carvalheiro, Joana, Torres, Joana, Fernandes, Alexandra, Giestas, Silvia, Mendes, Sofia, Agostinho, Claudia, Campos, Mario J. · Internet Archive